(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 44.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Rhythm Pharmaceuticals's revenue in 2025 is $174,334,000.On average, 16 Wall Street analysts forecast RYTM's revenue for 2025 to be $12,687,191,606, with the lowest RYTM revenue forecast at $11,766,234,033, and the highest RYTM revenue forecast at $13,538,076,320. On average, 16 Wall Street analysts forecast RYTM's revenue for 2026 to be $20,682,171,115, with the lowest RYTM revenue forecast at $17,331,353,743, and the highest RYTM revenue forecast at $25,724,080,146.
In 2027, RYTM is forecast to generate $37,396,883,701 in revenue, with the lowest revenue forecast at $29,953,811,375 and the highest revenue forecast at $48,041,951,993.